Comparative Pharmacology
Head-to-head clinical analysis: BRIELLYN versus OVULEN 28.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BRIELLYN versus OVULEN 28.
BRIELLYN vs OVULEN-28
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of ethinyl estradiol (estrogen) and norethindrone (progestin) that inhibits gonadotropin secretion, primarily suppressing ovulation and altering cervical mucus and endometrial lining.
Combination estrogen-progestin oral contraceptive that inhibits ovulation primarily by suppressing gonadotropin-releasing hormone (GnRH) from the hypothalamus, reducing follicle-stimulating hormone (FSH) and luteinizing hormone (LH) secretion, and altering cervical mucus and endometrial lining.
BRIELLYN (ethinyl estradiol / norethindrone) 1 tablet (0.035 mg ethinyl estradiol / 0.5 mg norethindrone) orally once daily at the same time each day.
One tablet (ethinyl estradiol 0.05 mg / ethynodiol diacetate 1 mg) orally once daily for 21 days followed by 7 days placebo; continuous cycle.
None Documented
None Documented
12-19 hours; clinical context: steady state reached in 3-5 days, dosing adjustment recommended in renal impairment
Ethinyl estradiol: 13-27 hours (mean ~17 hours); Norethindrone: 5-14 hours (mean ~8 hours). Clinical context: Steady state reached within 5-7 days.
Approximately 60% renal excretion of metabolites, 40% fecal/biliary elimination
Renal: ~50% as metabolites; Fecal/biliary: ~40% as conjugated metabolites; <1% unchanged in urine.
Category C
Category C
Oral Contraceptive
Oral Contraceptive